A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

Completed · Phase 1 · Has a placebo group

Conditions studied: Arthritis, Rheumatoid

In brief

The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).

Key facts

Study ID

NCT01484561

Run by

Pfizer

People needed

148

Starts

2012-04-01

Expected to finish

2013-02-01

Last updated by the study team

2014-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria.
• The patient must have active disease at both Screening and predose on Day 1 of Period 1.
• Patient must have had an inadequate response to at least one disease-modifying antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or intolerance.

You may not qualify if…

• Pregnant or lactating women
• Serious medical conditions that would make treatment with CP-690,550 potentially unsafe.
• A patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. In particular, a history of allergy to iodine, povidone-iodine, iohexol or other iodinated contrast media.

Where it is running

• Pfizer Investigational Site — South Miami, Florida, United States
• Pfizer Investigational Site — Albany, New York, United States
• Pfizer Investigational Site — Duncansville, Pennsylvania, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Tacoma, Washington, United States
• Pfizer Investigational Site — Prague, Czechia
• Pfizer Investigational Site — Berlin, Germany
• Pfizer Investigational Site — Erlangen, Germany
• Pfizer Investigational Site — Würzburg, Germany
• Pfizer Investigational Site — Mérida, Yucatán, Mexico
• Pfizer Investigational Site — Bialystok, Poland
• Pfizer Investigational Site — Bydgoszcz, Poland
• Pfizer Investigational Site — Warsaw, Poland
• Pfizer Investigational Site — Warsaw, Poland
• Pfizer Investigational Site — Wroclaw, Poland
• Pfizer Investigational Site — Moscow, Russia
• Pfizer Investigational Site — Petrozavodsk, Russia
• Pfizer Investigational Site — Saint Petersburg, Russia
• Pfizer Investigational Site — Saint Petersburg, Russia
• Pfizer Investigational Site — Seoul, South Korea
• Pfizer Investigational Site — Seville, Sevilla, Spain
• Pfizer Investigational Site — Barakaldo, Vizcaya, Spain
• Pfizer Investigational Site — Bilbao, Vizcaya, Spain
• Pfizer Investigational Site — A Coruña, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.